MediumCardiologyHeart failure with reduced ejection fractionca-mccqe1ca-rcpsc-im
A 68-year-old man with chronic HFrEF (LVEF 30%) due to ischaemic cardiomyopathy is clinically stable. He is on maximally tolerated ACE inhibitor, evidence-based beta-blocker and spironolactone. His eGFR is 60 mL/min/1.73 m², potassium 4.6 mmol/L, and he has type 2 diabetes. According to the 2021 CCS heart failure guideline, what additional therapy has the strongest evidence for reducing heart failure hospitalisation and cardiovascular death?